CTNI-51. NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM

RTOG 3508/AbbVie M13-813/INTELLANCE-1 was a phase 3 trial of depatuximab-mafodotin (depatux-m, formerly ABT-414) that accrued 639 patients with EGFR-amplified newly diagnosed GBM. At the pre-specified interim OS analysis, the futility criteria were met and there was no survival benefit from adding d...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Wefel, Jeffrey S, Won, Minhee, Lassman, Andrew, Stern, Yaakov, Wang, Tony, Aldape, Kenneth, Armstrong, Terri, Vogelbaum, Michael, Sulman, Erik, Moazami, Golnaz, Macsai, Marian, Gilbert, Mark, Bain, Earle, Blot, Vincent, Gan, Hui, Preusser, Matthias, Ansell, Peter, Samanta, Suvajit, Kundu, Madan, Seidel, Clemens, de Vos, Filip, Hsu, Sigmund, Cardona, Andres, Lombardi, Giuseppe, Bentsion, Dmitry, Peterson, Richard, Gedye, Craig, Lebrun-Frenay, Christine, Wick, Antje, Pugh, Stephanie, Curran, Walter, Mehta, Minesh
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Clinical Trials: Non-Immunologic
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650869/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.217
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares